| Biomarker ID | 859 |
| PMID | 22302227 |
| Year | 2012 |
| Biomarker | Interleukin 1 (IL-1β) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in Treatment Group [Treatment:0.56 (0.45–0.90) Vs Control : 0.34 (0.25–0.52)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Interleukin-1 processing,Interleukin-12-mediated signaling events,Folate metabolism,Leptin signaling pathway,RAGE pathway |
| Experiment | ADT Treatment Vs No Treatment |
| Type of Biomarker | Predictive |
| Cohort | 37 ADT-naïve men with locally advanced or recurrent prostate cancer. Of those, 23 initiated ADT with a gonadotropin-releasing hormone (GnRH) agonist and 14 served as nontreatment controls. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.026 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IL1B |